Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors

QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx Biopharmaceuticals presented a poster outlining Phase 1 and Phase 2 results for perifosine, an oral anti-cancer signal transduction inhibitor compound, for the treatment of patients with advanced sarcoma. Results of the Phase 1 and Phase 2 studies of perifosine showed an overall clinical benefit rate (CBR) of 52% which compares favorably with the activity of mTOR inhibitors. The poster titled, "Perifosine (P) an active agent in the treatment of patients with advanced sarcoma": R. Birch, S. Chawla, J. Nemunaitis, P. Savage, P. Kaiser, A. Spira, A. Cervera, E. Middleman, E. Sausville, M. Knowling, I. Henderson, was presented Sunday, June 3, 2007 at the American Society of Clinical Oncology's (ASCO) Annual Meeting currently being held in Chicago, Illinois.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We are very encouraged by the data from these Phase 1 and Phase 2 trials confirming single agent activity with perifosine in patients with advanced sarcomas, comparable to the activity of mTOR inhibitors."

Background

Perifosine is a novel oral alkylphospholipid that targets the PI3K pathway upstream from mTOR by inhibiting the phosphorylation of Akt. Perifosine's activity against sarcomas has now been evaluated in 145 patients enrolled in one of three Phase 1 trials or four Phase 2 trials. Five of these trials have been published.

    Methods


    Dose categories were as follows:


    -------------------------------------------------------------------------

    Lower Dose                           Higher Dose

    ----------------------------------------------------
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:7/29/2014)... --  Health 2.0 announces Bernard Tyson , CEO ... Eric Topol , Patrick Soon-Shiong , and Samsung,s President ... Annual Fall Conference this coming Sept. 21-24 in ... is set to host the very first Wearable Tech Fashion ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The panel ...
(Date:7/28/2014)... Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... and audio webcast to discuss financial results for the second ... July 31, 2014 at 4:30 p.m. ET. ... July 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the ...
(Date:7/28/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye has ... conference call with investors to July 31, 2014 at ... rescheduled the release date and conference call to enable ... Hideo Watanabe , President of STAAR Japan, who passed ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2
... 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: ... pharmaceutical company specializing in the development, manufacturing, and marketing ... that the annual general meeting of shareholders (the "Meeting") ... 10 a.m. Beijing time. The meeting will be held ...
... 10, 2012 The " Ablation ... " analyzes and studies the major market drivers, restraints, ... the World. Browse market data tables ... Ablation Technologies Market (2011-2016) - Global Trends & Competitive ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets 2Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets 3
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims to ... a bikini in the near future. This has caught the ... “Our Lean and Lovely review shows that it ... Neither your age nor your body shape matters, which means ... beginning, you will achieve the results that you have been ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Consilium Staffing, Your ... year-over-year at the halfway point of 2014, with strong indications ... the second half of this year. , “This is a ... Vice President of Consilium Staffing. , “We are proud ... the year, but we are even more excited about how ...
(Date:7/29/2014)... 2014 The Multiple System Atrophy Coalition, ... the appointment of five new members to its Board ... the election of its executive directors. The MSA ... and 2 Physician Advisors. These 12 dedicated volunteers ... of education, support, advocacy and research funding for the ...
(Date:7/29/2014)... Launched in 2012 by veteran anesthesiologist ... hangovers earlier this year at its Vegas location. Having ... the publication of research data related to the 20,000 ... The only licensed medical practice dedicated to the study, ... 2012 and treated thousands of patients within the first ...
(Date:7/29/2014)... brides want their bridal dresses and bridal parties to ... sure to provide designs of wedding gowns and bridesmaids ... has recently announced its new collection of gorgeous lace ... come with big savings, up to 61% off. , ... working in the garment industry for several years; they ...
Breaking Medicine News(10 mins):Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 4Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3Health News:LunaDress’ Summer Sale Has Arrived: All Its Gorgeous Lace Wedding Dresses are Affordable Now 2
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
Convenience, Protection, Comfort and Security -- FirstChoice pouches are your product of choice if you are looking for the convenience of a one-piece pouch that is either cut-to-fit or pre-cut to you...
Built-in convexity means added security and skin protection for recessed, retracted and flush stomas...pre-cut openings. Security and confidence achieved by the internal No-Flowback Valves and soft d...
... the skin over extended wearing time ... is the barrier of choice for ... benefit of it being discreet in ... and confidence assured with internal non-reflux ...
Inquire...
Medicine Products: